Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ZEVRA THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for ZEVRA THERAPEUTICS, INC.

ZVRA

ZEVRA THERAPEUTICS, INC.

About ZEVRA THERAPEUTICS, INC.

Zevra Therapeutics is a biotech company focused on developing and commercializing therapies for rare diseases. Its portfolio includes approved products like AZSTARYS and OLPRUVA, and late-stage candidates such as MIPLYFFA for Niemann-Pick disease type C. The company leverages proprietary technology, strategic acquisitions, and collaborations to address unmet medical needs in niche markets worldwide. Its business model emphasizes innovation, targeted commercialization, and pipeline expansion in the rare disease space.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ZEVRA THERAPEUTICS, INC.

1
1
ZEVRA THERAPEUTICS, INC. Zevra Therapeutics Reports 77.5% Revenue Increase to $36.2 Million in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ZEVRA THERAPEUTICS, INC. Zevra Therapeutics Reports $83.2 Million Net Income and Revenue Growth in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ZEVRA THERAPEUTICS, INC. Zevra Therapeutics Reports $26.1 Million in Quarterly Revenues, Significant Financial Improvements

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ZEVRA THERAPEUTICS, INC. Zevra Therapeutics Reports 487% Revenue Increase to $25.9 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ZEVRA THERAPEUTICS, INC. Zevra Therapeutics Reports $20.4 Million Revenue and $3.1 Million Net Loss in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ZEVRA THERAPEUTICS, INC. Zevra Therapeutics Reports $105.5 Million Net Loss for 2024, Revenue Declines to $23.6 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ZEVRA THERAPEUTICS, INC. Zevra Therapeutics Reports Net Loss of $33.2M, Increased Expenses, and Debt in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments